Nanohale AG (ETR:FYB) | WebDisclosure

PRESS RELEASE

published on 10/02/2025 at 06:30, 5 months 24 days ago

Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron
Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron. Commercial launch expected in Q4/2026

Formycon Regeneron Valorum Biologics Aflibercept Biosimilar Patent Disputes
BRIEF

published on 09/17/2025 at 16:00, 6 months 9 days ago

Formycon AG : Recherche et prévisions de performance actualisées

Prévisions De Revenus Formycon FYB202 Biosimilaires FYB206
BRIEF

published on 09/17/2025 at 16:00, 6 months 9 days ago

Formycon AG: Updated Research and Performance Forecast

Revenue Forecast Biosimilars Formycon FYB202 FYB206
PRESS RELEASE

published on 09/17/2025 at 15:55, 6 months 9 days ago

Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research GmbH updates rating on Formycon AG (ISIN: DE000A1EWVY8) to Buy with a target price of €48. Analyst expects revenue to rebound in H2 and Q4 due to FYB202 and FYB206 developments

First Berlin Equity Research BUY Rating Formycon AG Update Target Price
BRIEF

published on 09/17/2025 at 06:35, 6 months 9 days ago

Horus Pharma rejoint la commercialisation du biosimilaire Eylea® de Formycon

Commercialisation Formycon Biosimilaire Baiama Horus Pharma
BRIEF

published on 09/17/2025 at 06:35, 6 months 9 days ago

Horus Pharma Joins Formycon's Eylea® Biosimilar Commercialization

Commercialization Biosimilar Formycon Baiama Horus Pharma
PRESS RELEASE

published on 09/17/2025 at 06:30, 6 months 9 days ago

Horus Pharma becomes additional commercialization partner for Formycon's Eylea® biosimilar FYB203 in selected European countries under the brand name Baiama®
Horus Pharma partners with Formycon for Eylea biosimilar commercialization in Europe under Baiama brand. Agreement includes upfront payments and royalties for Klinge. Aflibercept treats nAMD

Agreement Formycon Eylea Biosimilar Horus Pharma Baiama Brand
BRIEF

published on 08/13/2025 at 06:35, 7 months 13 days ago

Formycon Affirms Full-Year Outlook After Strategic Developments

Formycon AG Corporate Bond Biosimilar Market 2025 Financial Guidance FYB202 & FYB206
BRIEF

published on 08/13/2025 at 06:35, 7 months 13 days ago

Formycon confirme ses perspectives pour l'ensemble de l'année après des développements stratégiques

Formycon AG Obligations D'entreprise Orientations Financières 2025 Marché Des Biosimilaires FYB202 Et FYB206
PRESS RELEASE

published on 08/13/2025 at 06:30, 7 months 13 days ago

Formycon confirms full-year guidance following business development in line with plan – working capital raised
Formycon AG confirms full-year guidance with successful business development. Working capital raised through oversubscribed corporate bond. Strong second half expected

Working Capital Business Development Formycon AG Corporate Bond Full-year Guidance

Published on 03/26/2026 at 23:00, 4 hours 46 minutes ago

FutureGen Industries Announces Closing of Debt Settlement
Published on 03/26/2026 at 22:05, 5 hours 41 minutes ago

BlackBerry to Announce Fourth Quarter and Fiscal Year 2026 Results on April 9, 2026
Published on 03/26/2026 at 22:00, 5 hours 46 minutes ago

Clean Air Metals Receives Provincial Funding and Provides Update on the Thunder Bay North Project
Published on 03/26/2026 at 22:00, 5 hours 46 minutes ago

Green Bridge Metals Reports Visible Copper Sulfide Mineralization in Initial 2026 Titac Drilling, Duluth Complex Minnesota
Published on 03/26/2026 at 21:00, 6 hours 46 minutes ago

Worksport Reports Record FY 2025 Results, Issues $35M–$42M 2026 Revenue Guidance; Targets Initial Cash Flow Positivity

View all ACCESSWIRE

Published on 03/26/2026 at 20:48, 6 hours 58 minutes ago

Dermapharm Holding SE repurchases 4,299,190 shares under its public share buyback offer
Published on 03/26/2026 at 19:20, 8 hours 26 minutes ago

Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
Published on 03/26/2026 at 19:13, 8 hours 33 minutes ago

Director Declaration
Published on 03/26/2026 at 19:09, 8 hours 37 minutes ago

2CRSi SA: Résultats 1er Semestre 2025/26 : Chiffre d'Affaires 204,7 M€ (x9,8) EBITDA de 9,6 M€ (x4,6)
Published on 03/26/2026 at 19:09, 8 hours 37 minutes ago

2CRSi SA: First Half 2025/26 Results: Revenue of €204.7 million (x9.8) EBITDA of €9.6 million (x4.6)

View all EQS

Published on 03/26/2026 at 18:17, 9 hours 29 minutes ago

Eiffage se renforce au capital de Getlink et porte sa participation à 29,40 % du capital
Published on 03/26/2026 at 18:17, 9 hours 29 minutes ago

Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 18:00, 9 hours 46 minutes ago

Arrêté des comptes au 31 décembre 2025 et perspectives 2026
Published on 03/26/2026 at 18:00, 9 hours 46 minutes ago

Calendrier financier 2026
Published on 03/26/2026 at 18:00, 9 hours 46 minutes ago

LABORATOIRES EUROMEDIS - Fin du contrat de liquidité

View all LES ECHOS COMFI WIRE

News